French Startup Robeauté Develops Rice-Sized Microrobot for Precision Neurosurgery

French medical technology firm Robeauté is advancing the development of a microrobot, comparable in size to a grain of rice, designed to execute complex brain procedures with high accuracy and minimal invasiveness. This technology aims to substantially enhance patient safety during critical interventions, such as obtaining tumor biopsies, by reducing collateral tissue trauma.

The precision of the device is enabled by a propulsion system utilizing rotating silicone rings to navigate the delicate cerebral architecture. This mechanism allows the robot to operate with an accuracy on the order of half a millimeter, surpassing the control offered by conventional rigid instruments. The microrobot traverses the brain at a controlled speed of approximately 3 millimeters per minute, following curvilinear paths while minimizing disruption to surrounding neural structures. Access to the surgical site requires only a minute, one-millimeter incision, which directly mitigates risks such as cerebral edema or hemorrhage.

Once positioned, the device can perform microbiopsies, safely acquiring minute tissue samples from deep or obstructed tumors—tasks previously classified as exceptionally high-risk. Navigational integrity is maintained through advanced artificial intelligence (AI) processing detailed Magnetic Resonance Imaging (MRI) scans to pre-calculate optimal, collision-free routes around functionally critical regions. Real-time procedural monitoring is provided by an integrated ultrasound localization system affixed to the skull, offering surgeons continuous feedback to sustain submillimeter accuracy during the operation.

Robeauté, a Paris-based startup founded in 2017 by Bertrand Duplat and Joana Cartocci, has secured significant backing, including a recent funding round totaling €27.2 million (approximately $29 million), which included strategic investment from Brainlab. Following successful preclinical evaluations in sheep that reportedly showed no significant complications like hematomas, the company is scheduled to commence international human clinical trials in 2026, involving medical centers in the United States and Germany.

The modular architecture suggests a broad spectrum of future applications beyond biopsy collection, including targeted therapeutic agent delivery, continuous physiological monitoring, or the precise implantation of electrodes for conditions like Parkinson's disease. CEO Bertrand Duplat noted the potential of microrobots to bring unparalleled access for precision medicine, addressing the difficulty current treatments face in crossing the blood-brain barrier. Robeauté is targeting an international launch by 2030, which could reshape neurosurgery into a more precise and safer discipline, ultimately improving prognoses for patients with intricate neurological pathologies.